News

From 1 January 2025, new rules on the labelling and packaging of medicines will come into effect across the United Kingdom, including Northern Ireland, under the Windsor Framework. These rules will prohibit prescription medicines in Northern Ireland from being labelled with European Union (EU) safety features. The requirements of the EU Falsified Medicines Directive (FMD) for medicines marketed and supplied in Northern Ireland will no longer apply.

Italy and Greece are the two countries that were granted the longest transition period of 6 years for the implementation of the Falsified Medicines Directive. Accordingly, from February 9, 2025, the European Medicines Verification System must also be operational in these countries, where active preparations are currently underway.

Study supporting the report on trends in the falsification of medicinal products and measures provided according to Directive 2011/62/EU.

2023. gada beigās Somijas Zāļu verifikācijas organizācija (FiMVO) nomainīja zāļu verifikācijas sistēmas (FiMVS) piegādātāju. Piegādātājs tika nomainīts no Arvato uz Solidsoft Reply (SSR). Šī pārmaiņa bija pirmais šāda veida gadījums Eiropas Zāļu verifikācijas sistēmas (EMVS) ekosistēmā. Tā iezīmēja nozīmīgu brīdi FiMVO misijā nodrošināt farmaceitiskās piegādes ķēdes integritāti un drošību Somijā.

On May 23, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2024 from the National Medicines Verification Organizations (NMVOs) were approved. Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane were re-elected as observers for the second consecutive year, representing the small countries group.

The European Commission has published a new version of the Questions & Answers (Q&A) document on “Safety Features for Medicinal Products for Human Use (V.21)”.